Scabies
Conditions
Interventions
Albendazole treatment
Sponsors
CENTER FOR DETECTION AND TREATMENT OF LEPROSY AND BURULI ULCER OF POBE
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: To be included in the study, patients must have all of the following criteria - Classic scabies, according to the IACS consensus criteria, confirmed by dermoscope examination - Patient living in the Plateau or Ouémé department - Patients who can be re-evaluated in consultation on day 28 and day 60 following inclusion - Consent to participate in the study (consent form written in the main languages spoken in the Plateau and Ouémé departments) - For women of childbearing age: agreement to use contraception for two weeks following inclusion.
Exclusion criteria
Exclusion criteria: Non-inclusion criteria Patients with at least one of the following characteristics will not be included in the study: - Subjects under 2 years of age or weighing less than 15 kg - Other associated skin conditions such as psoriasis, urticaria, dermatitis, acropustulosis, which may interfere with clinical evaluation - Known pregnancy, breastfeeding - Severe scabies (crusted scabies, diffuse scabies); scabies complicated by active impetigo - Known hypersensitivity to albendazole or any of the excipients - Treatment for scabies in the previous 3 months - Current or planned treatment within the next 2 weeks that is contraindicated in combination with albendazole (rifampicin, ritonavir, etc.) - Known or suspected neurocysticercosis - Known immune deficiency (HIV infection, treatment with immunosuppressants) or suspected immune deficiency (current or recent opportunistic disease) - Known active liver disease - Presence of a child under one month of age in the cluster (contraindication to benzyl benzoate) - Subjects who do not have a single family home - Subjects living in a cluster of more than 18 people - Homeless subjects Exclusion criteria Investigators will inform patients who meet all the inclusion criteria and none of the non-inclusion criteria about the trial. Those who agree to participate will sign the consent form and undergo blood tests to assess the exclusion criteria. Those with any of the following characteristics will be excluded from the study : - Pregnancy - HIV-positive serology - Increase in transaminases (AST and/or ALT) to more than 1.5 times the upper limit of normal
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response to albendazole, as assessed by the proportion of patients meeting the criteria for cure, i.e. complete resolution of pruritus, burrows, vesicles, and papules, OR complete resolution of burrows, vesicles, papules, but with pruritus considered to be post-scabies | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients who experience relapse after successful albendazole treatment, as assessed by the proportion of patients with confirmed scabies at visit 4 who met the criteria for cure at day 28. ;The proportion of subjects with pruritus in the index case cluster at baseline;The proportion of subjects with pruritus at baseline in the index case cluster who are cured of their pruritus 28 days after treatment initiation;The proportion of patients with post-scabies syndrome 28 days after albendazole initiation;Treatment compliance among patients included in the study;Treatment compliance among subjects in the index case cluster ;Adverse events in patients attributable to treatment with albendazole. | — |
Countries
Benin
Contacts
Public ContactPERRIN CATRAYE
PUBLIC HEALTH PHYSICIAN OF CENTER FOR DETECTION AND TREATMENT OF LEPROSY AND BURULI ULCER OF POBE
Outcome results
None listed